Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 369, Issue 10, Pages 985-986Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc1302145
Keywords
-
Categories
Ask authors/readers for more resources
A retrospective analysis of selected patients with glioblastoma who received treatment for cytomegalovirus with their anticancer treatment showed surprisingly good 2-year survival. A randomized trial is needed. To the Editor: Cytomegalovirus (CMV) DNA and proteins are expressed in several types of human cancers and metastases(1) but not in healthy surrounding tissues, suggesting a possible role for the virus in the cancer.(2) The malignant brain tumor glioblastoma has a dismal prognosis, with a median overall survival of 12 to 14 months and a 2-year survival of 15 to 26%. We examined more than 250 cases of glioblastoma (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Of these patients, only 1 was CMV-negative. Of the 75 patients we evaluated, the median rate ...
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available